Does Humana Cover Liraglutide? Formulary, Prior Auth, and Appeal Guide

What Liraglutide Is and Why Coverage Gets Complicated

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. The FDA approved the 1.2 mg and 1.8 mg subcutaneous doses as Victoza for type 2 diabetes management in 2010 [1], and the higher 3.0 mg dose as Saxenda for chronic weight management in adults with a body mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related comorbidity, in 2014 [2]. These two approvals created two completely different formulary pathways inside the same insurer.

The distinction matters because Congress historically prohibited Medicare from covering weight-loss drugs. That prohibition, rooted in the Social Security Act, still shapes most Medicare Advantage formularies today even after partial policy expansions [3]. Humana's Commercial products are not bound by that federal rule, so coverage patterns diverge sharply depending on whether you hold a group Commercial plan, an individual Marketplace plan, or a Medicare Advantage contract.

Clinically, liraglutide's weight-loss credentials are well established. The SCALE Obesity and Prediabetes trial (N=3,731) published in the New England Journal of Medicine in 2015 showed a mean weight loss of 8.4 kg with liraglutide 3.0 mg versus 2.8 kg with placebo at 56 weeks (P<0.001) [4]. A separate SCALE Diabetes sub-study (N=846) demonstrated 6.0% mean weight loss in patients with type 2 diabetes versus 1.9% with placebo [5]. Those data support both indications and form the backbone of prescribers' coverage arguments during prior-authorization submissions.

For cardiovascular benefit in diabetes, the LEADER trial (N=9,340) showed liraglutide reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 13% versus placebo over a median 3.8-year follow-up (HR 0.87; 95% CI 0.78, 0.97; P<0.001 for non-inferiority, P=0.01 for superiority) [6]. The FDA updated the Victoza label to include a cardiovascular risk-reduction indication [1], which is a separate justification prescribers can invoke on Humana prior-authorization forms.

How Humana's Formulary Tiers Affect Your Cost

Humana structures most of its Commercial formularies across five tiers, with specialty drugs typically landing on Tier 4 or Tier 5. Victoza (liraglutide for diabetes) appears on Tier 3 or Tier 4 on many Humana Commercial group plans, while Saxenda (liraglutide for weight loss) is more commonly on Tier 4 or excluded outright [7]. Tier placement directly determines your cost-sharing before and after the deductible.

On a Humana Medicare Advantage Part D plan, the situation is more constrained. CMS guidance specifies that plans are not required to cover drugs used for "anorexia, weight loss, or weight gain" under standard Part D formulary rules [8]. The practical effect: most Humana MA-PD formularies omit Saxenda entirely. Victoza may appear if the prescribing diagnosis code is diabetes, but approvals for weight management alone are routinely denied.

The American Diabetes Association's 2024 Standards of Care in Diabetes state that "for patients with type 2 diabetes who need to lose weight, GLP-1 receptor agonists with evidence of weight loss, such as semaglutide and liraglutide, are preferred agents" [9]. Citing that language verbatim in a prior-authorization letter can strengthen the medical necessity argument when the treating diagnosis is T2D rather than obesity alone.

The HealthRX Coverage Decision Framework below classifies Humana liraglutide scenarios by plan type and diagnosis:

| Scenario | Typical Formulary Status | PA Required | Step Therapy | |---|---|---|---| | Commercial group, T2D diagnosis, Victoza | Tier 3-4, covered | Yes | Metformin + 1 oral agent | | Commercial individual, weight loss, Saxenda | Tier 4 or excluded | Yes | Structured diet program | | Medicare Advantage, T2D diagnosis, Victoza | Covered on select plans | Yes | Metformin + 1 oral agent | | Medicare Advantage, weight loss, Saxenda | Excluded on most plans | N/A (not covered) | N/A | | Marketplace ACA plan, weight loss, Saxenda | Varies by metal level | Yes | Program documentation |

Prior Authorization Criteria Humana Typically Requires

Humana's prior-authorization process for liraglutide follows criteria that align with the FDA-approved label and major guideline thresholds [2]. Prescribers should anticipate submitting documentation across several domains.

For Victoza (T2D indication):

• Confirmed type 2 diabetes diagnosis with HbA1c typically above 7.0% or 8.0% (threshold varies by plan year) [9]
• Documentation that the patient has tried metformin for at least 90 days at an adequate dose, unless metformin is contraindicated or not tolerated
• Statement of cardiovascular risk or established ASCVD if invoking the cardiovascular risk-reduction indication [6]
• Prescriber attestation that the patient is not using concurrent GLP-1 therapy

For Saxenda (weight management indication):

• BMI of 30 or greater, or BMI of 27 or greater with documented comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or T2D) [2]
• Participation in a structured behavioral weight-management program of at least 16 weeks, depending on the plan
• Documentation of at least two prior pharmacologic or non-pharmacologic weight-loss attempts
• Prescriber specialty or affiliation with an obesity medicine program (required by some Humana Commercial group plans)

The Obesity Medicine Association's clinical practice guidelines note that "pharmacotherapy for obesity should be considered an adjunct to, not a replacement for, lifestyle intervention" [10]. Humana reviewers apply similar language when evaluating Saxenda requests, so behavioral program documentation is rarely optional.

Turnaround times for Humana commercial PA decisions run 3 to 5 business days for standard requests and 72 hours for urgent requests. Medicare Advantage decisions must be issued within 72 hours for standard requests under CMS regulations [8].

Step Therapy: What Drugs Come Before Liraglutide on Humana

Step therapy means you must try and fail at least one formulary-preferred drug before Humana will approve liraglutide. For the diabetes indication, the standard Humana step sequence runs:

1. Metformin (first-line, generic, Tier 1)
2. A sulfonylurea such as glipizide or glimepiride (Tier 1-2) or SGLT2 inhibitor such as empagliflozin (Tier 2-3) [11]
3. DPP-4 inhibitor such as sitagliptin (Tier 2-3), if the prescriber documents that sulfonylurea caused hypoglycemia or is otherwise inappropriate
4. Liraglutide (Victoza), approved after documented failure or intolerance of the above

For the weight-management indication, step therapy typically requires:

1. Documentation of 6 months of caloric restriction and physical activity with inadequate response
2. Trial of phentermine/topiramate extended-release (Qsymia) or bupropion/naltrexone (Contrave) for 12 weeks with less than 5% weight loss, on plans that require pharmacologic step therapy

Several U.S. states have enacted step-therapy protection laws that limit how long an insurer can require step therapy and mandate an expedited exception pathway. The National Conference of State Legislatures tracks these statutes [12]. Patients on Humana Commercial plans governed by state law can invoke those protections in writing before completing the full step sequence.

How to Appeal a Humana Liraglutide Denial

Denials happen. The internal Humana appeal process and the external review process follow distinct timelines and require different documentation.

Step 1: Internal Humana Appeal (Level 1)

File within 60 days of the denial notice for Commercial plans, or within 60 days for Medicare Advantage. Submit a written appeal letter that includes: the treating clinician's signature, the specific clinical rationale citing peer-reviewed evidence (LEADER [6], SCALE [4], ADA Standards [9]), a completed Letter of Medical Necessity, and copies of all prior treatment attempts. Humana must respond within 30 calendar days for standard Commercial appeals and within 7 calendar days for Medicare Advantage standard appeals [8].

Step 2: External Review

For Commercial plans, patients can request independent external review through the state insurance commissioner's office or through a CMS-certified independent review organization after exhausting internal appeals. For Medicare Advantage, the external review body is MAXIMUS Federal Services, the CMS-contracted Qualified Independent Contractor. MAXIMUS must issue a decision within 72 hours for expedited cases and 7 calendar days for standard cases [8]. Reversal rates at the external review stage for GLP-1 drugs industry-wide run approximately 40 to 60%, based on published insurer report data [13].

Step 3: Medicare-Specific Escalation

If MAXIMUS denies the appeal, Medicare Advantage members can escalate to the Office of Medicare Hearings and Appeals (OMHA), then to the Medicare Appeals Council, and finally to federal district court if the amount in controversy exceeds $1,870 (2025 threshold). Each level has specific filing deadlines, so timely action after each denial letter is essential.

A 2023 report from the HHS Office of Inspector General found that Medicare Advantage plans denied 13% of prior authorization requests that met Medicare coverage criteria [14]. That statistic is directly citable in an appeal letter to demonstrate that denial rates exceed clinical justification rates across the industry.

What to Include in a Liraglutide Medical Necessity Letter

The medical necessity letter is the single most influential document in a prior-authorization or appeal submission. An effective letter includes:

• Patient-specific HbA1c trajectory or weight history over 12 to 24 months with objective measurements
• Explicit reference to the FDA-approved indication and the specific liraglutide dose being requested [2]
• Direct quotation from the ADA 2024 Standards of Care recommending GLP-1 agonists in patients with T2D and cardiovascular disease [9]
• Peer-reviewed citations showing clinical outcome data, specifically LEADER for cardiovascular risk reduction [6] and SCALE for weight outcomes [4]
• Statement of why alternative agents are contraindicated, less effective, or already failed
• ICD-10 codes matching the clinical scenario (E11.65 for T2D with hyperglycemia, E66.01 for morbid obesity due to excess calories)
• Prescriber's NPI and DEA numbers, plan member ID, and date of service

The American Association of Clinical Endocrinology (AACE) 2022 Clinical Practice Guideline for Metabolic and Bariatric Surgery explicitly supports GLP-1 receptor agonist therapy for patients with obesity and T2D who are not surgical candidates [15]. That endorsement from a specialty society carries weight with Humana medical reviewers.

Novo Nordisk Savings Cards and Cash-Pay Alternatives

Novo Nordisk offers the Victoza Savings Card and the Saxenda Savings Card for commercially insured patients [16]. These cards can reduce out-of-pocket costs to as low as $5 per 30-day fill in some cases, subject to program eligibility limits. Key restrictions:

• Not valid for patients enrolled in Medicare, Medicaid, CHIP, TRICARE, or any other federal or state government health program [16]
• Maximum annual savings caps apply (typically $3,600 to $7,200 per year depending on the program year)
• Patients must reside in the United States and have a valid prescription
• The card cannot be used at mail-order pharmacies on some Commercial plans

The Victoza list price runs approximately $948 per 30-day supply as of mid-2025. Without insurance or a savings card, a 90-day supply at a compounding pharmacy using semaglutide (a different GLP-1 agent) may cost $300 to $500, though the FDA has issued guidance warning against compounded semaglutide from 503A and 503B facilities now that the shortage designation has been removed [17]. Compounded liraglutide faces similar regulatory scrutiny.

For patients who cannot access savings cards (Medicare beneficiaries, for example), the Extra Help / Low Income Subsidy program through CMS can reduce Part D drug costs substantially for qualifying individuals [18]. Income and asset thresholds for Extra Help eligibility are updated annually by CMS.

GoodRx cash pricing for liraglutide (Victoza, 3 mL pen, 6 mg/mL) runs approximately $800 to $950 per fill at major retail pharmacies as of July 2025. No FDA-approved generic liraglutide exists as of this writing; the drug's patent protection and biologic complexity have delayed generic entry [19]. Biosimilar development is underway but no biosimilar has received FDA approval in the U.S. market.

Liraglutide vs. Other GLP-1 Agents on the Humana Formulary

Humana formularies in 2025 list several GLP-1 receptor agonists, and the preferred agent varies by plan. Semaglutide (Ozempic for T2D, Wegovy for weight loss) and dulaglutide (Trulicity) are often placed on Tier 3, sometimes at a lower tier than liraglutide, because Humana has negotiated specific rebate contracts with manufacturers [20]. That means a patient who is denied Victoza may actually find Ozempic or Trulicity covered with fewer step-therapy barriers on the same Humana plan.

Prescribers should check the specific Humana plan formulary using the drug lookup tool on Humana's website or call Humana pharmacy services at 1-800-281-6918 before submitting a PA for liraglutide specifically. The FDA-approved dosing for weekly semaglutide (Ozempic) starts at 0.25 mg weekly and can be titrated to 2.0 mg weekly for T2D [21], while liraglutide requires daily injection. Some patients prefer daily dosing for flexibility; others find weekly injection more convenient. That patient preference, documented in the chart, can justify liraglutide over semaglutide in a PA submission.

The SUSTAIN-6 cardiovascular outcomes trial (N=3,297) showed semaglutide reduced MACE by 26% versus placebo (HR 0.74; 95% CI 0.58, 0.95; P<0.001 for non-inferiority) [22]. Comparing LEADER and SUSTAIN-6 data, both agents show statistically significant cardiovascular benefit, so the choice between them on clinical grounds alone is often a matter of injection frequency and tolerability rather than efficacy hierarchy.

Practical Steps to Get Liraglutide Covered by Humana

A clear sequence shortens the coverage timeline. Work through these steps with your prescribing clinician:

1. Obtain the current Humana formulary document for your specific plan (not a generic Humana formulary) and confirm liraglutide's tier and PA requirements for the year.
2. Ask the prescriber's office to submit a PA at least 3 weeks before the anticipated first fill date to allow for resubmission if the first attempt is denied.
3. Provide the prescriber with objective records: HbA1c values over the past 12 months, body weight measurements, medication history with dates and doses, and any comorbidity documentation.
4. If denied, request the specific denial reason code in writing within 24 hours of receiving the denial notice. Humana is required to provide this [8].
5. Submit the Level 1 appeal within 60 days, attaching peer-reviewed citations (LEADER [6], SCALE [4], ADA Standards [9], AACE guidelines [15]).
6. If denied again, file the external review request immediately. Do not wait to see if the insurer reconsiders voluntarily.
7. Simultaneously, ask the prescriber to write a bridge prescription using the Novo Nordisk savings card on a Commercial plan, or identify a patient assistance program if you are on Medicare.

Prescribers who specialize in endocrinology or obesity medicine tend to have pre-written PA templates and appeal letters on file, which can reduce the time from denial to approval by 2 to 3 weeks compared with a primary care practice submitting its first liraglutide PA.